Article Text
Short report
Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)
Abstract
Efficacy and safety of long term use of FK506 (2–4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects.
- AChR, acetylcholine receptor
- ADL, activities of daily living
- MG, myasthenia gravis
- clinical study
- FK506
- myasthenia gravis